Publications by authors named "R P Steeds"
Article Synopsis
- ARVC is a rare genetic condition that increases the risk of serious heart problems and requires effective risk assessment to prevent severe cardiac events.
- A study involving 83 ARVC patients showed that those experiencing major adverse cardiac events (MACE) had notably lower right ventricular global longitudinal strain (RV GLS) and right ventricular free wall longitudinal strain (RVFWLS) compared to those without MACE.
- The findings suggest that measuring RVFWLS can be a better predictor of MACE than traditional echocardiographic methods for assessing right ventricular function.
Background: Fabry disease (FD) causes multiorgan sphingolipid accumulation, with cardiac involvement responsible for the largest burden of morbidity and mortality. Exercise intolerance in FD is prevalent, yet the mechanisms of this are poorly understood. The aim of this study was to assess exercise intolerance in FD and identify whether this correlates with the phase of cardiomyopathy.
View Article and Find Full Text PDFImportance: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive cardiomyopathy that commonly presents with concomitant chronic kidney disease. Chronic kidney dysfunction is associated with worse outcomes, but the prognostic value of changes in kidney function over time has yet to be defined.
Objective: To assess the prognostic importance of a decline in estimated glomerular filtration rate (eGFR) in a large cohort of patients with ATTR-CM.
Importance: Development of myocardial fibrosis in patients with aortic stenosis precedes left ventricular decompensation and is associated with an adverse long-term prognosis.
Objective: To investigate whether early valve intervention reduced the incidence of all-cause death or unplanned aortic stenosis-related hospitalization in asymptomatic patients with severe aortic stenosis and myocardial fibrosis.
Design, Setting, And Participants: This prospective, randomized, open-label, masked end point trial was conducted between August 2017 and October 2022 at 24 cardiac centers across the UK and Australia.